Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

Adjuvant durvalumab did not improve disease-free survival in patients with early-stage non-small cell lung cancer in the phase 3 BR.31 trial.

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

While presenting the Union Budget for 2024-25 in the Lok Sabha, Finance Minister Nirmala Sitharaman proposed to cut customs ...

NPPA directs manufacturers to reduce MRP of anti-cancer drugs following government's tax exemptions and duty reductions.

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

The government instructed pharmaceutical companies to reduce prices on the anti-cancer drugs Trastuzumab, Osimertinib, and ...

NPPA asks companies to revise MRP of three anti-cancer drugs and submit information: Gireesh Babu, New Delhi Tuesday, October 29, 2024, 16:15 Hrs [IST] The National Pharmaceutical ...

Recent results from the NIAGARA trial, which evaluated using the immune checkpoint inhibitor durvalumab in combination with ...